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Abstract
Background: Naturally occurring autoantibodies against amyloid-β (nAbs-Aβ) have been shown to exert beneficial
effects on transgenic Alzheimer’s disease (AD) animals in vivo and on primary neurons in vitro. Not much is known
about their effect on microglial cells. Our aim was to investigate the effect of nAbs-Aβ on amyloid-β (Aβ)-treated
microglial cells in vitro with respect to cell viability, stress pathways, cytokine production and phagocytotic abilities
and whether these effects can be conveyed to neurons.
Methods: Primary microglial cells isolated from Swiss Webster mouse mesencephalons on embryonic day 13.5
were pretreated with nAbs-Aβ and then treated with Aβ oligomers. After 3 hours, phagocytosis as well as western
blot analysis were evaluated to measure the amount of phagocytized Aβ. Cell viability was analyzed using an MTT
assay 24 hours after treatment. Pro-inflammatory cytokines in the supernatants were analyzed with ELISAs and then
we treated primary neuronal cells with these conditioned microglia supernatants. Twenty-four hours later we did a
MTT assay of the treated neurons. We further investigated the effect of a single nAbs-Aβ administration on Tg2576
mice in vivo.
Results: Upon co-administration of Aβ and nAbs-Aβ no change in microglia viability was observed. However, there
was an increase in phosphorylated p38 protein level, an increase in the pro-inflammatory cytokines TNF-α and IL-6
and an increase in Aβ uptake by microglial cells. Treatment of primary neurons with conditioned microglia medium
led to a 10% improvement in cell viability when nAbs-Aβ were co-administered compared to Aβ-treated cells
alone. We were unable to detect changes in cytokine production in brain lysates of Tg2576 mice.
Conclusions: We provide evidence on the mechanism of action of nAbs-Aβ on microglia in vitro. Interestingly, our
in vivo data indicate that nAbs-Aβ administration should be considered as a therapeutic strategy in AD, since there
is no inflammatory reaction.
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Background
Alzheimer’s disease (AD) is a neurodegenerative disorder
leading to the loss of cholinergic neurons in the brain,
characterized by extracellular amyloid-β (Aβ) deposits and
the formation of neurofibrillar tangles comprising hyper-
phosphorylated tau protein inside the cell. The toxicity of
Aβ deposits is conveyed by oligomeric aggregates that lead
to synaptic dysfunction and apoptosis of neurons [1,2].
Active immunization strategies using different forms of
Aβ have been extensively tested in amyloid precursor pro-
tein (APP) transgenic mouse models. The initial animal
results were promising [3,4], but since active immunization
in AD patients was associated with considerable side
effects [5] and some patients did not develop Aβ-antibody
titers [6], passive immunization strategies came into focus.
Treatment with humanized monoclonal antibodies [7] as
well as passive immunization with intravenous immuno-
globulins (IVIg) has been investigated in pilot clinical trials
[8,9]. The rationale for its use is that IVIg contain naturally
occurring autoantibodies against Aβ (nAbs-Aβ). Naturally
occurring autoantibodies in the central nervous system are
involved in maintaining homeostasis by removing debris
and are known to prevent inflammation [10]. The benefi-
cial effects of nAbs-Aβ have been shown both in vitro on
primary neurons and neuronal cell lines as well as in vivo
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in transgenic mice [11,12]. The effect of IVIg on microglial
cells has already been investigated by other groups. It has
been shown that IVIg reduce phagocytosis in vitro via
Fc receptors [13], IVIg induce tumor necrosis factor-α
(TNF-α) and nitric oxide (NO) in a dose-dependent man-
ner, whereas the greater the IgM/IgA content the higher
the impact on microglial cells [14], and that IVIg enhance
the secretion of matrix metalloproteinase 9, which seems to
play a role in the pathogenesis of multiple sclerosis [15].
Referring to Aβ, Magga et al. found an increase in Aβ clear-
ance when they administered IVIg in a dose-dependent
manner on primary microglial cells [16]. IVIg depleted of
nAbs-Aβ did not promote clearance, indicating that the
enhanced clearance effect is mediated by nAbs-Aβ. In a
study on the immortalized murine microglial cell line BV-2,
administration of IVIg restored cells’ viability and enhanced
phagocytotic ability of fibrillar Aβ [17]. In addition to these
results, IVIg are limited in their availability and we there-
fore decided to use nAbs-Aβ in our study. Theoretically,
these will be able to be cloned eventually and therefore the
problem of availability can be overcome. In all experiments
we used the negative fraction of IVIg, which contains all
antibodies except those that were purified with the affinity
chromatography, and we were not able to see the same
effects as those obtained with nAbs-Aβ, coming to the con-
clusion that nAbs-Aβ are the active substance in IVIg
responsible for the beneficial effects with regard to AD.
The effect and the interaction, however, of nAbs-Aβ on
microglial cells have not been investigated to date. This is
especially important as microglia are purported to have a
major role in the pathogenesis and propagation of AD [18].
Upon stimulation, microglial cells can react in many differ-
ent ways, including phagocytosis, the secretion of immuno-
modulating cytokines and finally programmed cell death in
order to kill pathogens or restore tissue integrity [19]. Acti-
vated microglial cells have been found surrounding plaques
in histopathological sections of AD patients [20] and their
role in the phagocytosis of all forms of Aβ has been investi-
gated. Due to the immune-stimulating effect of foreign
monoclonal antibodies in the human body, we were inter-
ested in the effect of nAbs-Aβ on primary microglial cells.
In the following experiments we investigated the effect of
nAbs-Aβ on Aβ-treated microglial cells with respect to cell
viability, neuroinflammation and phagocytosis, and whether
any effect on primary neurons is conveyed by treated
microglial cells.
Material and methods
All chemicals were obtained from Sigma-Aldrich, St.
Louis, MO, USA unless indicated otherwise.
Antibodies
Antibodies against the following proteins were used: Aβ
(clone 6E10, Covance, Princeton, NJ, USA), phosphorylated
(phospho) p38, horseradish peroxidase (HRP)-conjugated
secondary antibodies (all Cell Signaling Technology, Danvers,
MA, USA), glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (Novus Biologicals, Littleton, CO, USA), allo-
phycocyanin (APC)-conjugated CD11b (eBioscience, San
Diego, CA, USA).
Cells
Primary microglial cell culture
For the isolation of primary microglial cells we used a
protocol based on that described by Saura et al. [21].
Microglial cells were derived from embryonic day 13.5
(E13.5) Swiss Webster mouse mesencephalons. Briefly,
meninges-free mesencephalons were isolated, collected
and homogenized in Leibovitz L-15 medium (PAA
Laboratories, Pasching, Austria). After centrifugation cells
were resuspended in Dulbecco's modified Eagle’s medium
(DMEM) with L-glutamine (Lonza, Basel, Switzerland)
containing 10% fetal bovine serum (FBS) (PAA Laborator-
ies, Pasching, Austria), 100 U/mL penicillin and 100 μg/mL
streptomycin (Lonza, Basel, Switzerland) and plated on
polyethyleneimine (PEI)-coated plates. After 7 days cells
were stimulated with granulocyte-macrophage colony-
stimulating factor (GM-CSF) (Roche, Basel, Switzerland).
Cells were subplated on PEI-coated plates and used for
experiments on day in vitro 14 to 19.
Primary cortical neuron cell culture
Neurons were cultured from cortices of E13.5 Swiss Webster
mice. Briefly, meninges-free cortices were isolated, col-
lected and homogenized in Leibovitz L-15 medium and
resuspended in Neurobasal-A Medium (Invitrogen, Grand
Island, NY, USA) supplemented with B27 (Gibco, Basel,
Switzerland), 100 U/mL penicillin and 100 μg/mL strepto-
mycin and L-glutamine and plated on PEI-coated plates.
Cells were used for experiments on day 6 to 8.
Animals
Twenty- to 22-month-old heterozygous adult female
Tg2576 mice expressing mutant APPSWE (695(K670N,M671L)
under the control of the hamster prion promoter in a hy-
brid C57Bl/6 × SJL background and age- and gender-
matched non-transgenic wild-type control mice (WT) were
used for all experiments. Tg2576 and WT mice were ran-
domly divided into groups of five to six, independent of
genotype and treatment, on a 12 hour light–dark schedule
(lights on 07:00 to 19:00). They had free access to tap water,
were fed ad libitum and kept under standard conditions.
The sample sizes of the groups were as follows: transgenic
(Tg) control n = 5, Tg nAbs-Aβ n = 5, WT n = 6. All
animal procedures were approved by the office of the
district president and the Institutional Animal Care and
Use Committee.
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Administration of nAbs-Aβ to mice
Mice were treated intraperitoneally (i.p.) with nAbs-Aβ
(400 μg dissolved in 0.2 ml of physiological saline solu-
tion) or vehicle (0.2 ml physiological saline solution).
The mice were sacrificed 24 hours later and samples
were taken. Brains were immediately frozen in liquid ni-
trogen and stored at −80°C.
Preparation of oligomeric Aβ
Aβ oligomers were synthesized according to Kayed et al.
[22]. Briefly, lyophilized synthetic Aβ42 peptide (PSL,
Heidelberg, Germany) was initially monomerized by dis-
solving in hexafluoroisopropanol (HFIP) and separated
into aliquots in low-binding tubes. HFIP was evaporated
and aliquots were stored at −20°C until use. The peptide
film was resuspended in ultrapure water with a final
concentration of 232 μM. A small magnetic stirrer was
added and the peptide solution was stirred for 48 hours
at room temperature at 1400 rpm.
Preparation of nAbs-Aβ
nAbs-Aβ were isolated from IVIg as previously described
[11]. Briefly, we used purified intravenous IgG (Octagam
5%). Ninety-six percent of protein represents normal
human IgG (IgA <0.2 mg; IgM <0.1 mg). IgG subclasses
are fully represented (IgG 1, 65%; IgG 2, 30%; IgG 3, 3%;
IgG 4, 2%). To ensure homogenous orientation of the Aβ
peptide to the affinity column, a cysteine residue was intro-
duced at the N-terminal part of the peptide. The azlactone-
activated support contains an iodoacetyl group (Ultralink;
Perbio, Bonn, Germany) at the end of a hexadecyl-spacer
group, which reacted with the cysteinyl-sulfhydryl group to
yield a stable thioether linkage in order to reduce steric hin-
drance and provide maximum binding capacity of the anti-
bodies. The bound antibodies were eluted from the column
with 10 × 0.5 ml 0.1 M glycine buffer, pH 2.8. Each fraction
was collected in a microreaction tube containing 35 μl 1 M
Tris–HCl, pH 9. IVIg depleted of nAbs, termed flow-
through (ft), was also collected and used as a negative con-
trol in experimental settings. To maintain the integrity of
the antibodies, a neutral pH was adjusted immediately after
elution by adding the appropriate amount of Tris-HCI or
glycine buffer. nAbs-Aβ and ft were sterile filtered and
stored at −20°C until use.
Cell viability assessment
Quantification of cell viability was performed using the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) reduction assay. Microglial cells were treated with
oligomeric Aβ42 (5 μM) and/or nAbs-Aβ or ft (both 0.1
μM and 1 μM) for 24 hours in DMEM without FBS.
Medium was changed to medium containing 0.5 mg/mL
MTT and incubated for 1 hour. Medium was removed and
cells were solubilized with dimethyl sulfoxide (DMSO)
(AppliChem, Darmstadt, Germany) and shaken for 30 min-
utes. The absorbance was measured at 570 nm on a plate
reader. Neuronal cells were treated with supernatants of
microglial cells. Neurobasal-A medium was removed and
conditioned medium from microglial cells was added. After
24 hours, medium was replaced with DMEM containing
0.5 mg/mL MTT and incubated for 1 hour and the assay
was performed as described above.
Measurement of TNF-α, IL-1β, IL-6 and interferon-γ
Primary microglial cells were pre-treated with nAbs-Aβ
or ft (0.1 μM) for 30 minutes and stimulated with oligo-
meric Aβ42 (5 μM) for 24 hours. Supernatants were stored
at −20°C until use. Mice brains were lysed using T-PER
lysis buffer (Pierce, Rockford, IL, USA) containing prote-
ase inhibitors (Roche Diagnostics, Mannheim, Germany).
Protein concentrations were determined using a spec-
trophotometer. Concentrations of TNF-α, interleukin-1β
(IL-1β), IL-6 and interferon-γ (IFN-γ) were quantified
using the Duoset enzyme-linked immunosorbent assay
(ELISA) system (R&D, Minneapolis, MN, USA) according
to the manufacturer’s protocol.
Western blot
Treated cells were washed twice with ice-cold phosphate-
buffered saline (PBS) and cells were lysed using M-Per sup-
plemented with protease and phosphatase inhibitors
according to the manufacturer’s protocol. The protein con-
centration of the cell lysates was determined using Nano-
Drop. Total cell protein was separated by 4 to 12% sodium
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred onto nitrocellulose membranes.
Membranes were blocked with 1 × Rotiblock (Carl Roth,
Karlsruhe, Germany) and incubated with the appropriate
primary antibody dilutions for Aβ (1:2000), phospho p38
(1:4000) or GAPDH (1:5000). Membranes were washed
with Tris-buffered saline containing 5% Tween20 and incu-
bated with secondary antibodies. Membranes were incu-
bated with SuperSignal™ West Dura Extended Duration
Substrate (Thermo Scientific, Rockford, IL, USA) and
exposed to an autoradiographic film (CL-Xposure Film,
Thermo Scientific, Rockford, IL, USA). Band intensity was
quantified using a densitometer.
Aβ phagocytosis assay
Fluorescein isothiocyanate (FITC)-labeled Aβ42 was oli-
gomerized as described above. Primary microglial cells
were pre-incubated with nAbs-Aβ or ft (0.1 μM) in
serum-free DMEM for 30 minutes at 37°C and then
treated with FITC-Aβ42 (5 μM) for 3 hours. For flow
cytometric analysis, microglial cells were rinsed twice
with ice-cold PBS, harvested, and washed with
fluorescence-activated cell sorting (FACS) buffer (PBS
with 0.1% FBS). Microglial cells were stained with APC-
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conjugated CD11b antibody, washed and resuspended in
FACS buffer containing HOECHST 33258 to sort vital
cells only. Measurements were performed with a LSR II
flow cytometer (Becton Dickinson, Franklin Lakes, NJ,
USA). Analysis was performed using FlowJo software
(Tree Star Inc., Ashland, OR, USA). Only vital and
CD11b+ cells were used for uptake comparison. Uptake
of the differently treated cells was evaluated by compar-
ing the mean fluorescence intensity of FITC. Levels of
Aβ phagocytosis were also determined by Western blot.
Statistical analysis
All results of in vitro as well as in vivo experiments are
presented as the mean ± SD. We used the Student’s t test
to assess the statistical significance of all experiments. For
all statistical comparisons, the following definitions were
used: P <0.05 (*), P <0.01 (**) or P <0.001 (***).
Results
nAbs-Aβ are not toxic to microglia
nAbs-Aβ have been shown to have beneficial effects on Aβ
oligomer-induced toxicity in neuronal cells [11,12]. It has
recently been reported that Aβ oligomers reduce viable
microglial cells in vitro [23]. We investigated the effect of
nAbs-Aβ on Aβ oligomer-induced toxicity (Figure 1). Cell
viability was reduced to 50% when stimulated with Aβ42
oligomers. nAbs-Aβ had no beneficial effect on the Aβ-
induced reduction in viability. nAbs-Aβ alone showed no
reduction in cell viability, nor did solvent-treated cells.
Effect of Aβ oligomers and co-administered nAbs-Aβ on
stress pathways and cytokine levels in vitro
Since Aβ-mediated cell viability was unaffected by nAbs-
Aβ, we investigated changes in intracellular stress pathways
upon stimulation with Aβ oligomers and in the presence
of nAbs-Aβ. We observed an increase in phospho p38
protein levels upon stimulation with Aβ oligomers alone
compared to untreated microglial cells (Figure 2A). nAbs-
Aβ alone also induced a slight increase in phospho p38
levels. However, co-administration of Aβ oligomers and
nAbs-Aβ led to a strong induction of phospho p38 with
protein levels increasing 10-fold compared to untreated
cells (Figure 2B).
Cytokine levels were examined after 24 hours co-treat-
ment. The results are consistent with the results
obtained from the phospho p38 stress-pathway investi-
gation: Aβ and nAbs-Aβ alone slightly increased TNF-α
(Figure 2C) and IL-6 (Figure 2D) levels, whereas co-
administration of both Aβ and nAbs-Aβ led to a strong
and significant induction in pro-inflammatory cytokine
levels. Co-administration of ft did not lead to the induc-
tion of cytokine levels (data not shown).
Influence of nAbs-Aβ on pro-inflammatory cytokines in
Tg2576 transgenic animals
After observing the induction of pro-inflammatory cyto-
kines in vitro following treatment of microglial cells with
nAbs-Aβ, we next evaluated cytokine concentration in
brain homogenates of wild-type animals as well as
Tg2576 mice. For all analyzed cytokines we were able to
detect upregulation in transgenic animals (Figure 3). IL-
1β was elevated by 58% compared to wild-type animals
(Figure 3A) (7.11 ± 2.05 vs. 11.23 ± 3.32, P <0.05), IFN-γ
levels (Figure 3B) in Tg2576 mice brain were increased
by 41% (19.78 ± 1.48 vs. 27.91 ± 8.00, P <0.05), TNF-α
(Figure 3C) was increased by 24% (93.16 ± 7.97 vs.
115.62 ± 9.95, P <0.05) and IL-6 (Figure 3D) showed an
increase of 24% (19.65 ± 1.48 vs. 24.45 ± 4.32, P <0.05),
respectively. Treatment of Tg2576 mice with nAbs-Aβ
did not lead to a significant induction or attenuation in
Figure 1 Aβ oligomers reduce cell viability, co-administered nAbs-Aβ do not attenuate cell death. Primary microglia cells were treated with
Aβ42 oligomers, cell viability was measured using the MTT assay. To investigate the effect of nAbs-Aβ, microglial cells were pre-incubated for 30 minutes
with different concentrations of nAbs-Aβ. Viability of untreated cells was referred to as 100% viability. Experiments were performed at least three times,
independently. nAbs-Aβ, naturally occurring autoantibodies against amyloid-β; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
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Figure 2 Co-administration of nAbs-Aβ and Aβ oligomers leads to a rise in phosphorylated p38 and TNF-α levels. Western blot analysis
was performed to detect protein levels of phosphorylated p38. GAPDH was used as loading control (A). Phospho p38 levels were evaluated
densitometrically and normalized to GAPDH (B). C + D show cytokine levels of Aβ-treated cells. Cells were treated for 24 hours and supernatants
were subjected to cytokine ELISA. ELISA experiments were performed at least three times, independently. GAPDH, glyceraldehyde 3-phosphate
dehydrogenase; ELISA, enzyme-linked immunosorbent assay; nAbs-Aβ, naturally occurring autoantibodies against amyloid-β; TNF-α, tumor
necrosis factor-α.
Figure 3 Injection of nAbs-Aβ does not change cytokine levels in Tg2576 mice brain lysates. Brain lysates of wild-type mice, Tg2576 mice
and Tg2576 mice treated with nAbs-Aβ for 24 hours were subjected to cytokine ELISA. Figure 3 shows cytokine levels for IL-1β (A), INF-γ (B),
TNF-α (C) and IL-6 (D). ELISA, enzyme-linked immunosorbent assay; IL, interleukin; INF, interferon; nAbs-Aβ, naturally occurring autoantibodies
against amyloid-β; TNF-α, tumor necrosis factor-α.
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the brain concentration of any of the aforementioned
cytokines.
nAbs-Aβ increase Aβ42 uptake in primary microglial cells
Aβ is taken up by microglial cells from the periphery
and it has been shown that the monoclonal antibody
6E10 increases the phagocytotic ability of microglial cells
[24]. To investigate the effect of co-administration of Aβ
oligomers and nAbs-Aβ on the phagocytotic abilities of
microglial cells in vitro, we used FITC-labeled Aβ42 and
FACS analysis. Figure 4A shows a histogram of the shift in
the mean fluorescence intensity of the cell population with
nAbs-Aβ pre-treatment. Co-administration of nAbs-Aβ
led to a doubling in the phagocytosis of Aβ42 oligomers
(Figure 4B). ft did not enhance phagocytosis, pointing to a
genuine effect of nAbs-Aβ.
Levels of phagocytosed Aβ were also determined by
western blotting (Figure 4C). The intensity of the protein
bands was evaluated densitometrically (Figure 4D). As
shown in Figure 4C and D the incubation of primary
microglial cells with Aβ and nAbs-Aβ led to a doubling in
phagocytosis. In contrast, no significant increase was
observed when using ft.
Supernatants of nAbs-Aβ-co-treated microglial cells have
beneficial effects on the viability of neurons compared to
supernatants of Aβ-treated microglial cells
To investigate a possible indirect effect of nAbs-Aβ on pri-
mary neuronal cells, we cultured neurons in the medium
of microglial cells treated with Aβ and/or nAbs-Aβ or ft
for 24 hours and assessed cell viability using the MTT
assay (Figure 5). Supernatants of microglial cells from
three independent preparations were applied to neurons
from three independent preparations. Compared to super-
natants from solvent-treated microglial cells, supernatants
from Aβ-treated microglial cells reduced the viability of
neuronal cells to 67%. Following the co-administration of
nAbs-Aβ to microglial cells, supernatants significantly
reduced the number of viable neuronal cells to 77%. Pre-
treatment with ft was not able to significantly restore the
viability of primary neuronal cells. In addition, treatment
with nAbs-Aβ alone was not harmful to neuronal cells.
Discussion
The positive effect of nAbs-Aβ on neuronal cells and the
fact that IVIg may exert beneficial effects on cognition
in AD patients has previously been established [9]. In
addition AD patients have reduced levels of nAbs-Aβ in
Figure 4 nAbs-Aβ enhance phagocytosis of Aβ oligomers in primary microglia. Histogram of the mean fluorescence intensity of FITC-Aβ
and FITC-Aβ and nAbs-Aβ (0.1 μM) co-treated cells (A). (B) shows the means of three independent experiments. Values were normalized to
FITC-Aβ42-treated cells. Cell lysates of Aβ42-treated cells were also subjected to western blot. To detect Aβ uptake, blots were probed with the
monoclonal Aβ antibody 6E10. GAPDH was used as loading control (C). (D) shows the densitometric evaluation of three independent
experiments; values are given normalized to GAPDH intensity. FITC, fluorescein isothiocyanate; GAPDH, glyceraldehyde 3-phosphate
dehydrogenase; nAbs-Aβ, naturally occurring autoantibodies against amyloid-β.
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the CSF and plasma compared to age-matched controls,
leading to the hypothesis that AD patients will have
increased Aβ plaque deposits [25]. In this study we investi-
gated the effect of nAbs-Aβ, isolated from IVIg, on Aβ-
exposed microglial cells with the emphasis on cytokine
production and phagocytosis of Aβ and whether changes
in these physiological actions can convey beneficial effects
to primary neurons.
Although the viability of neurons improves with the co-
administration of nAbs-Aβ in Aβ oligomer-treated cells
[11,12], we found no similar effects on the viability of
microglial cells. nAbs-Aβ alone did not influence cell viabil-
ity, an important property of nAbs-Aβ considering their
therapeutic use. Smith et al. provided evidence for a link be-
tween increased phagocytosis of Aβ and induction of apop-
tosis in BV-2 microglial cells [26]. This may also hold true
for the co-administration of nAbs-Aβ and could explain the
difference in the effect observed for neuronal cells. Com-
pared to the monoclonal antibody 6E10, nAbs-Aβ increased
pro-inflammatory TNF-α levels in vitro, whereas no signifi-
cant changes were observed for IL-6. With the additional
administration of Aβ oligomers TNF-α levels and IL-6 levels
rose significantly. Consistent with these results, we observed
a strong increase in the phosphorylation of the stress path-
way protein MAPK p38. There is contradictory evidence
regarding whether pro-inflammatory cytokines are benefi-
cial or harmful in AD; current data support the hypothesis
that it is a matter of the right equilibrium [27]. Small rises
in pro-inflammatory cytokines seem to have beneficial
effects, whereas the induction of excessive and prolonged
secretion of pro-inflammatory cytokines can lead to chronic
neuroinflammation and neurodegeneration. Neuroprotec-
tive effects, especially of TNF-α, have been reported. The
neuroprotective effect seems to be mediated by the
regulation of peroxide formation, calcium accumulation
and NF-κB activation [28]. It has been shown by several
groups that Aβ overexpression induces neuroinflammation
in the AD transgenic mouse models Tg2576 and B6.Cg-Tg
(APPswe, PSEN1dE9)85Dbo/J [29,30]. In our present
study, we also observed increased cytokine concentrations
in 22-month-old Tg2576 mice compared to their wild-type
littermates. In contrast to our in vitro experiments, admini-
stration of nAbs-Aβ to Tg2576 mice did not lead to an
increased inflammatory reaction as measured by intracer-
ebral cytokine levels. Instead IL-1β, TNF-α, IL-6 and IFN-γ
levels were unchanged following the administration of
nAbs-Aβ to Tg2576 mice. Although the brain is protected
by the blood–brain barrier, it has already been shown that
nAbs-Aβ can cross it [31]. In vivo studies provide an envir-
onment with astrocytes, neurons and microglial cells
whereas our in vitro experiments were performed using
microglial cells only. Von Bernhardi et al. observed that
microglia exposed to Aβ respond with reactive morpho-
logical changes, induction of inducible nitric oxide syn-
thase (iNOS), elevated nitric oxide production and
decreased reductive metabolism. All these responses were
attenuated by the presence of astrocytes [32]. Astrocytes
are also involved in Aβ degradation and removal and play
an important role in maintaining physiological homeostasis
in the brain. However, compared to microglial cells they do
not need a stimulus for phagocytosis and at the same time
phagocytosis cannot be enhanced by large amounts of IVIg
as it can be for microglial cells [16]. Further studies with
mixed glial cell cultures are needed to investigate this spe-
cific issue.
Interestingly, our observations contrast with those of
Minami and colleagues, who showed a profound induc-
tion of neuroinflammation following the administration
Figure 5 Beneficial effects of supernatants of nAbs-Aβ co-treated microglial cells on the viability of primary neurons. Supernatants
of treated microglial cells were subjected to primary neurons and incubated for 24 hours. Aβ concentration was 5 μM and nAbs/ft
concentration was 0.1 μM. Viability was assessed using MTT assay. Viability of control-treated cells was referred to as 100% viability. Figure 5
shows the means of at least three independent experiments. nAbs-Aβ, naturally occurring autoantibodies against amyloid-β; MTT,
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
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of monoclonal antibodies to mice [33]. One explanation
might be the use of a different animal model in the afore-
mentioned study compared to the Tg2576 mouse model
in our study. More likely, as a passive immunization strat-
egy, nAbs-Aβmay preclude a neuroinflammatory reaction,
unlike monoclonal antibodies in vivo. As we only treated
mice for 24 hours before measuring intracerebral cytokine
levels one could argue that longer treatment periods are
needed to assess the influence of administering anti-Aβ
antibodies on neuroinflammation. A study by Puli et al.
also showed significant suppression of TNF-α levels after
long-term treatment with IVIg in the APP/PS1 mouse
model of AD [34]. Nevertheless, long-term studies with
repeated administration of nAbs-Aβ and ft are needed to
investigate this issue further and to preclude a rise in pro-
inflammatory cytokines upon chronic nAbs-Aβ adminis-
tration in transgenic mice. With respect to the adverse
effects of active immunization observed in an early clinical
study, treatment with IVIg and/or nAbs-Aβ might prove a
safer approach [5]. By applying two different methods we
were able to show that phagocytosis of Aβ oligomers by
microglial cells doubles when nAbs-Aβ are pre-adminis-
tered. This effect was not observed with the same amount
of flow-through, indicating a highly specific effect of
nAbs-Aβ on the uptake of Aβ from microglial cells. This
might be attributed to the formation of antigen-antibody
complexes between nAbs-Aβ and Aβ oligomers, which
are preferentially taken up by microglial cells. Phagocytosis
of antigen-antibody complexes is usually mediated via the
Fcγ receptor [35]. In the experimental setup that we used,
microglial cells of murine origin were exposed to human
IgG. Human Fcγ receptor 1 and murine Fcγ receptor 1
share 65 to 75% homology in their extracellular domains
and it is known that human Fcγ receptor 1 can bind mur-
ine IgG [36]. Unfortunately, nothing is known on the
ability of murine Fcγ receptor 1 to bind to human IgG.
As our nAbs-Aβ preparation contains all IgG subclasses,
it might be worth testing them with regard to their influ-
ence on cytokine secretion and phagocytosis separately
in the future. Very recently Smith et al. developed a
mouse model where all murine Fcγ receptors have been
replaced by human Fcγ receptors [37]. It would be ideal
to test our human nAbs-Aβ on this mouse model to ver-
ify our results and to exclude the impact of species on
the immunoglobulin-Fc receptor interaction. However,
the positive effect of nAbs-Aβ on Aβ phagocytosis is con-
sistent with results obtained for monoclonal antibodies
[24]. Since the amyloid hypothesis postulates that an
increase in amyloid-β leads to neurodegeneration, nAbs-
Aβ support Aβ oligomer clearance. To determine
whether the changes observed for microglial cells have
beneficial effects on neurons, we treated primary neurons
with conditioned media from microglial cell cultures.
Interestingly, we were able to observe a significant
improvement in neuron viability from Aβ-treated micro-
glial cells compared to those with co-administered nAbs-
Aβ. This was not the case following co-administration of
flow-through. We can exclude that this effect is due to a
lower amount of Aβ in nAbs-Aβ-treated cell superna-
tants, even though we observed an increase in Aβ uptake.
It is possible that in the co-treated supernatants Aβ is
bound to nAbs-Aβ or even modulated in its aggregation
state and is therefore less toxic to the neuronal cells. An-
other explanation could be that the activated microglial
cells secrete neurotrophic factors, as it has been reported
for lipopolysaccharide (LPS)-treated microglial cells by
Nakajima et al. [38]. It is thus likely that simultaneous
stimulation of Aβ and nAbs-Aβ activates the same signal-
ing pathways in microglial cells that lead to the production
of neurotrophic factors. We measured one neurotrophic
factor (brain-derived neurotrophic factor (BDNF); data
not shown) but were unable to show a significant increase.
Other factors such as glial cell line-derived neurotrophic
factor (GDNF) may play a role in the observed effect, and
further studies are currently underway.
Conclusions
In summary, we investigated the effects of nAbs-Aβ iso-
lated from IVIg on microglial cells. Although we were not
able to rescue microglial cells upon stimulation with Aβ
oligomers we showed that nAbs-Aβ have positive effects
on the phagocytotic ability of Aβ oligomers. The beneficial
effect of microglial-conditioned media on primary neurons
is promising, and should be the focus of further research.
Our present data demonstrate that nAbs-Aβ are able to
enhance Aβ degradation and support neuronal survival
without inducing a cerebral inflammatory reaction as
shown by unchanged pro-inflammatory cytokine levels
in vivo. These findings support nAbs-Aβ as a potential
therapy to ameliorate Aβ-induced neuronal toxicity in AD.
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